Eton Pharmaceutcials financials
$59.19+0.02%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $80.0M | $39.0M | $31.6M | $21.3M | $21.8M | $39.0K | $959.0K | $0.00 |
| Gross profit | $42.7M | $23.4M | $21.1M | $14.3M | $19.0M | -$397.0K | $506.0K | $0.00 |
| Gross margin | 53.5% | 60.0% | 66.6% | 67.4% | 87.1% | −1017.9% | 52.8% | — |
| Operating income | -$844.0K | -$2.6M | -$1.2M | -$8.3M | -$1.5M | -$27.1M | -$18.6M | -$10.3M |
| Net income | -$4.6M | -$3.8M | -$936.0K | -$9.0M | -$2.0M | -$28.0M | -$18.3M | -$37.2M |
| Net margin | −5.8% | −9.8% | −3.0% | −42.4% | −9.0% | −71717.9% | −1910.3% | — |
| Diluted EPS | $-0.17 | $-0.15 | $-0.04 | $-0.36 | $-0.08 | $-1.33 | $-1.03 | $-5.80 |
| EBITDA | $3.2M | -$1.5M | -$291.0K | -$6.5M | -$1.0M | -$26.5M | -$18.2M | -$10.3M |
| Operating cash flow | $10.5M | $969.0K | $6.8M | $4.8M | -$4.7M | -$22.3M | -$18.0M | -$8.1M |
| Free cash flow | $10.2M | $943.0K | $6.8M | $4.8M | -$4.7M | -$22.4M | -$19.1M | -$8.4M |
| Diluted shares | 26.9M | 25.9M | 25.6M | 25.1M | 25.2M | 21.0M | 17.8M | 6.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $25.9M | $14.9M | $21.4M | $16.3M | $14.4M | $21.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $30.6M | $29.8M | $5.4M | $6.4M | $6.7M | $7.0M |
| Total assets | $92.1M | $76.1M | $31.7M | $25.0M | $27.5M | $26.3M |
| Total liabilities | $66.0M | $51.7M | $16.3M | $12.0M | $9.8M | $10.7M |
| Shareholders' equity | $26.2M | $24.4M | $15.5M | $13.1M | $17.6M | $15.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology